A.I. and psychedelics firing this morning 🚀

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 May 07, 2024 | [Read Online]( A.I. and psychedelics firing this morning 🚀 Good morning, 360! If you read our email yesterday, hopefully you took advantage of that MAJOR LEAK of [Jeff Bishop’s Bullseye plan](. See his insert below because he is ALREADY in and out of CAVA. Mind-blowing! FOCUS LIST🔎 AIRE - Up over 50% in the pre-market after announcing completion of previously announced acquisition of Naamche, an AI-powered solutions firm for large industries, including real estate. ESPR - Up over 24% in pre after reporting better than expected earnings, 467% year on year Q1 revenue growth CMND - Up over 30% in pre after securing exclusive global rights to breakthrough psychedelic compounds for PTSD treatment *sponsored by Sica Media We’ve featured some winning ideas lately in 360, and today we have another big play. Pull up NeuroOne Medical (NMTC) on your platform right now. It’s been mentioned here a few times in the past, and if you recall, we’ve seen some very nice trades from it.  It’s all about waiting for the right signals, and we just got one of our favorites – a new “GO” trend on the hourly chart (see below): You can see the trading levels we’re looking for [here](, including our full run-down. But on top of the “GO” signal that was recently fired, there are some other great catalysts that could drive NMTC right now. Including [this news]( that just came out about insider buying… I always say that insiders can sell for a lot of reasons… they only buy for one – they think it is going higher. As always, before you decide to trade the stock, make sure to do your due diligence and have a plan in place and stick to it! *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 AIRE - Up over 50% in the pre-market after announcing completion of previously announced acquisition of Naamche, an AI-powered solutions firm for large industries, including real estate. reAlpha Tech Corp. (AIRE) is a real estate technology company that commercializes artificial intelligence (AI)-powered technologies. The company offers and develops AI-based products and services to customers in the real-estate industry. In the after-hours yesterday, the [company announced]( the completion of its previously announced acquisition of Naamche, an AI-powered solutions firm for large industries, including real estate. As a result of the Acquisitions, reAlpha added a talented team of 43 AI engineers, developers, UX designers and creatives to its roster, who will conceptualize, design and implement real estate-focused digital products to meet the demand of a rapidly digitizing real estate industry. The stock traded up over 50% in the pre-market in reaction to the announcement. The $1.28 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $1.40, $1.50 and then the pre-market high at $1.54. Beyond that $1.68 and $2 come into play. Below $1.28, targets to the downside are $1.20, $1.10, $1 and then a gap fill at $0.8565. ESPR - Up over 24% in pre after reporting better than expected earnings, 467% year on year Q1 revenue growth Esperion Therapeutics Inc.(ESPR) is a pharmaceutical company that develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). In the pre-market this morning, the [company reported]( Q1 earnings. Highlights include: – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 Total net income for the quarter was $61.0 million, compared to a net loss of $61.7 million for the comparable period in 2023. Basic net income per share was $0.36, compared to basic and diluted net loss per share of $0.79 for the comparable period in 2023. Diluted net income per share was $0.34. As of March 31, 2024, cash and cash equivalents totaled $226.6 million The stock traded up over 24% in the pre-market in reaction to the earnings report. The $2.55 area acted as support in the pre-market and now becomes a potential support level. Above it, targets to the upside are $2.66 and then the pre-market high at $2.72. Beyond that, $3 and $3.40 come into play. Below $2.55, targets to the downside are $2.40, $2.32 and then a gap fill at $2.12. 🎯BULLSEYE BOMBSHELL “Not the worst thing you could learn for $47!” *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. Already in and out of YESTERDAY’s Pick of the Week. Pocketed $9800 on buying options and the stock in the first trading hour! Did you miss another one?  [Fix that today!]( CMND - Up over 30% in pre after securing exclusive global rights to breakthrough psychedelic compounds for PTSD treatment Clearmind Medicine Inc. (CMND) is a clinical pharmaceutical company that develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. In the pre-market this morning, the [company announced]( that it had secured exclusive global rights to breakthrough psychedelic compounds for PTSD treatment. CMND announced the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. The stock traded up over 50% in the pre-market in reaction to the news. The $1.70 area was resistance and then acted as support in the pre-market. Above it, targets to the upside are $1.80 and then the pre-market high at $1.85. Beyond that, $2.08, $2.50 and $3 come into play. Below $1.70, targets to the downside are $1.50, $1.38, and then a gap fill at $1.17.  MARKET NEWS 📰 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull *PAID ADVERTISEMENT. Raging Bull has currently been paid twelve thousand five hundred dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on May 7. 2024. Raging Bull had previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on march 26. 2024. Raging Bull was also previously paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on March 4, 2024. Raging Bull was previously paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /company search FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America